5.4.2.11: phosphoglycerate mutase (2,3-diphosphoglycerate-dependent)
This is an abbreviated version!
For detailed information about phosphoglycerate mutase (2,3-diphosphoglycerate-dependent), go to the full flat file.
Word Map on EC 5.4.2.11
-
5.4.2.11
-
enolase
-
aldolase
-
isozyme
-
2-phosphoglycerate
-
glyceraldehyde-3-phosphate
-
glycogen
-
creatine
-
mutases
-
triosephosphate
-
phosphofructokinase
-
muscle-specific
-
cofactor-independent
-
cramp
-
myoglobinuria
-
triose
-
bb
-
fructose-2,6-bisphosphatase
-
phosphohistidine
-
tpi
-
warburg
-
phosphoenzyme
-
fructose-bisphosphate
-
aldoa
-
brugia
-
malayi
-
medicine
-
biofuel production
-
drug development
- 5.4.2.11
- enolase
- aldolase
- isozyme
- 2-phosphoglycerate
- glyceraldehyde-3-phosphate
- glycogen
- creatine
- mutases
-
triosephosphate
-
phosphofructokinase
-
muscle-specific
-
cofactor-independent
- cramp
- myoglobinuria
- triose
- bb
- fructose-2,6-bisphosphatase
-
phosphohistidine
- tpi
-
warburg
- phosphoenzyme
-
fructose-bisphosphate
- aldoa
-
brugia
- malayi
- medicine
- biofuel production
- drug development
Reaction
Synonyms
2,3-bisphosphoglycerate-dependent PGAM, 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase, alpha-PGAM, B-type PGM, cofactor-dependent phosphoglycerate mutase, dPGAM, DPGM, dPGM-B, EC 2.7.5.3, EC 3.1.3.13, EC 5.4.2.1, EntD, PGAM, PGAM1, PGAM2, PGM, phosphoglycerate mutase, phosphoglycerate mutase 1, phosphoglycerate mutase type B, Phosphoglyceromutase, Rv3214, ScPGM, SSO2236, Sts-1
ECTree
5.4.2.11 phosphoglycerate mutase (2,3-diphosphoglycerate-dependent)Advanced search results
results (
results (Inhibitors
Inhibitors on EC 5.4.2.11 - phosphoglycerate mutase (2,3-diphosphoglycerate-dependent)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
1-benzyl 4-[(3R,4R,6R)-6-[1-(hex-5-ynoyloxy)-1-methylethyl]-1-oxaspiro[2.5]oct-4-yl] (2R)-2-(2,3-dihydro-1H-indol-3-ylmethyl)butanedioate
i.e. MJE3, spiroepoxide with anti-proliferative effects in human breast cancer cells. MJE3 covalently inactiviates enzyme at K100
2,5-bis(trifluoromethyl)-N-(1,2,8-trihydroxy-9-oxo-9Hxanthen-3-yl)benzenesulfonamide
-
3-(trifluoromethoxy)-N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
3-chloro-N-(1,8-dihydroxy-9-oxo-9H-xanthen-3-yl)-2-fluorobenzenesulfonamide
-
3-cyano-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzene-1-sulfonamide
less than 10% inhibition at 0.02 mM
4-(piperidin-1-yl)-N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
4-(pyrrolidin-1-yl)-N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
4-(tert-butyl)-N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
4-(tert-butyl)-N-(1,8-dihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
4-(tert-butyl)-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
4-(trifluoromethyl)-N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
4-bromo-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
4-chloro-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
4-cyano-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzene-1-sulfonamide
less than 10% inhibition at 0.02 mM
4-cyclohexyl-N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
-
4-cyclohexyl-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
4-fluoro-N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
6-([1,1'-biphenyl]-4-sulfonamido)-8-hydroxy-9-oxo-9H-xanthen-2-yl acetate
-
metavanadate
-
less than 5% residual activity at 10 mM after 10 min incubation
-
N-(1,2,8-trihydroxy-9-oxo-9H-xanthen-3-yl)-[1,10-biphenyl]-4-sulfonamide
-
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-1-phenylmethanesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-2,5-bis(trifluoromethyl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-3-(trifluoromethoxy)benzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-4-(piperidin-1-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-4-(pyrrolidin-1-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-4-(trifluoromethyl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-4-iodobenzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-4-methylbenzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)-[1,10-biphenyl]-4-sulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)benzenesulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)naphthalene-1-sulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-2,8-dimethoxy-9-oxo-9H-xanthen-3-yl)naphthalene-2-sulfonamide
less than 10% inhibition at 0.02 mM
N-(1-hydroxy-5-methoxy-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
N-(1-hydroxy-5-methyl-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
N-(1-hydroxy-7-methoxy-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
N-(1-hydroxy-7-methyl-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
N-(1-hydroxy-7-nitro-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
N-(7-chloro-1-hydroxy-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
N-(7-fluoro-1-hydroxy-9-oxo-9H-xanthen-3-yl)-[1,1'-biphenyl]-4-sulfonamide
-
tetrathionate
-
inactivation of MM-type isozyme, 50% of MB-type, BB-type not affected
vanadate
acting as a substrate mimic, enzyme binding structure, overview
